- Published on
Malaria's Drug Resistance Is Becoming Alarmingly Sophisticated, Study Finds
- Authors
- Name
- DeepHorus
A new genetic analysis has revealed that Plasmodium falciparum, the parasite responsible for the deadliest form of malaria, is stockpiling drug resistance adaptations in increasingly complex combinations. The study, published in Nature Microbiology, highlights a dual threat to malaria control: lingering resistance to retired drugs and growing threats to current frontline therapies. Researchers warn that this evolutionary arms race is making the pathogen more difficult to treat.
Malaria remains one of the world's deadliest infectious diseases, infecting hundreds of millions and killing hundreds of thousands annually, mostly children under five in Africa. P. falciparum has developed resistance to nearly every antimalarial drug developed in the past 70 years, including artemisinin, discovered in the 1970s. Partial artemisinin resistance, first seen in Southeast Asia over 15 years ago, has now spread to multiple African locations.
In the new study, researchers sequenced drug-resistance genes from 605 P. falciparum samples collected across 15 Ethiopian districts between 2019 and 2023. They found chloroquine resistance markers in 61.2 percent of 492 successfully classified samples, despite chloroquine being withdrawn for P. falciparum treatment decades ago. Markers for sulfadoxine-pyrimethamine resistance were present in 42.8 percent of 453 samples, even though that drug has not been used for malaria in Ethiopia since 2005.
The persistence of chloroquine resistance is likely tied to the continued use of chloroquine against P. vivax, a separate malaria parasite that overlaps geographically with P. falciparum. This ongoing drug pressure may be maintaining resistance traits that could re-emerge if chloroquine is ever reconsidered. The geographical patterns support this interpretation, though researchers say more investigation is required.
The study also found that markers for current treatments are spreading, including the main marker for artemisinin partial resistance. This raises significant concerns about the effectiveness of artemether-lumefantrine, the current first-line combination drug in Ethiopia. The parasite appears to be simultaneously carrying resistance to multiple drug classes, complicating treatment strategies.
“These findings underscore the dual challenge of persistent resistance to discontinued drugs and rising threats to current frontline therapies,” the researchers said. The team emphasized the need for continued genomic surveillance and a deeper understanding of how overlapping drug pressures shape parasite evolution.
Looking ahead, the result highlights the urgent need for new antimalarial compounds and smarter combination strategies. As the parasite's resistance machinery becomes more sophisticated, the global health community must accelerate efforts to stay ahead in this arms race. Without decisive action, the progress made against malaria over the past two decades could be reversed.
